Erle Frayne Argonza
Good morning from Manila!
A heartwarming news from India and Vietnam concerns the reduction of prices of vaccines for cholera. To recall, India is among the countries that lead in bringing down pharmaceutical costs, thus saving the day for many poorer folks in the south who are relentlessly victimized by the rent-seeking practices of Western drug companies.
Enjoy your read!
Cheaper cholera vaccine passes pilot trial
23 June 2008 | EN | 中文
The current international cholera vaccine is too expensive for developing countries
A reformulated oral vaccine against cholera promises to be an affordable and effective weapon to combat the disease for people living in endemic areas of developing countries, according to a new study.
The internationally licensed cholera vaccine currently available is too expensive for use in developing countries, where it is most needed.
Vietnam produces its own two-dose oral cholera vaccine and distributes it through its public health system at US$0.40 a dose. Nine million doses have been delivered so far.
To kick-start the process of scaling up this vaccine in developing countries around the globe, the vaccine was reformulated to comply with WHO standards.
Researchers from India, Korea and Sweden conducted a pilot trial of the vaccine at Kolkota’s Infectious Diseases Hospital in eastern India. Cholera is endemic in Kolkota.
The study evaluated the vaccine’s safety and efficacy outside Vietnam.
Participants were healthy and included 101 adults aged 18–40 years and 100 children aged 1–17 years. They received two random doses of either the vaccine or a placebo, 14 days apart.
After immunization, 53 per cent of the adults and 80 per cent of the children showed at least a four-fold increase in their antibody levels against Vibrio cholerae O1, the predominant strain of cholera-causing bacteria.
Safety tests revealed that “no adverse event occurred more frequently in the vaccinated than in the placebo group”, say the researchers.
“Cholera affects a large number of children in developing countries, and so a vaccine that is safe and effective for children sounds impressive, and the development as a whole appears to be a step towards global rolling out of the cholera vaccine,” says Sumana Kanjilal, associate professor of paediatric medicine at Calcutta National Medical College Hospital, India.
The reformulated vaccine is now undergoing a trial in around 70,000 people in Kolkata. “If the vaccine is found to be safe and protective, this could pave the way for the use of this vaccine in the control of cholera worldwide,” the researchers write.
The study was published in PLoS ONE.